Floatz logo

2-OXAZOLIDINONE, 4-((1S)-1-FLUOROETHYL)-3-(2-(((1S)-1-(4-METHYL-2'-(TRIFLUOROMETHYL)(3,4'-BIPYRIDIN)-6-YL)ETHYL)AMINO)-4-PYRIMIDINYL)-, (4R)-

Advanced Malignancies That Harbor IDHR132 Mutations

Novartis PharmaceuticalsSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced Malignancies That Harbor IDHR132 Mutations cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

2-OXAZOLIDINONE, 4-((1S)-1-FLUOROETHYL)-3-(2-(((1S)-1-(4-METHYL-2'-(TRIFLUOROMETHYL)(3,4'-BIPYRIDIN)-6-YL)ETHYL)AMINO)-4-PYRIMIDINYL)-, (4R)- is also rated in:

gliomaDormant
CCC
Indicative ·
49 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →